Virovet
Leuven
About Virovet
ViroVet is a pioneering company dedicated to the development of disruptive and innovative technologies for the control of viral diseases in livestock, with antiviral drugs for respiratory disease complexes and innovative vaccines for viral infections in swine leading the pipeline. The livestock industry is a 100+ billion-euro industry. Viral diseases cost producers billions every year in losses and threaten the world supply of animal protein. The strategy of ViroVet is to provide novel solutions to be used alone or in combination with vaccines and biosecurity measures in order to provide livestock producers, national governments and international organizations with a multi-faceted arsenal of virus control weapons against endemic and epizootic viral diseases. It is clear that with the growing world population there is an increased demand for more protein-rich diets. With the increasing density of the livestock industry, the intensifying global trade and climate changes, there is an ever increased risk for the global spread of viral diseases, severely damaging livestock industry. ViroVet has already enlisted the support of a number of key opinion leaders (KOLs) in livestock medicine confirming the extensive market for antiviral drugs and novel vaccines addressing the challenges of spreading viral diseases. KOLs feel that ViroVet’s products have the potential to reduce the use of antibiotics and revolutionize the livestock industry worldwide.
Company Facts
- Operating status: Active
- Company type: For Profit
- IPO status: Private
- Employees: 11 – 50
- Estimated revenue: $1K – $10K
- Total funding: $6.6M
- Funding stage: Early Stage Venture
- Last round: Series B (May 2020)
- Website: virovet.com
- Phone: 32-16-299726
Industries & Categories
Biotechnology, Pharmaceutical, Veterinary
Social Profiles
Canonical: https://fsome.com/organization/virovet-89049 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.